George M. Low Center for Industrial Innovation

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Retrieved on: 
Saturday, October 14, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Pharmacokinetics, KRAS, RAMP, NSCLC, AACR, Dana–Farber Cancer Institute, ORR, Toxicity, Safety, Lung cancer, Mutation, RAS, George M. Low Center for Industrial Innovation, Cancer, Clinical research, DLT, Harvard Medical School, Verastem Oncology, Associate, MAPK, Conference, Patient, Pharmaceutical industry, Medicine

The results will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • The results will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023 in Boston, Massachusetts.
  • The pharmacokinetic profile of avutometinib in combination with sotorasib was similar to results in monotherapy studies.
  • Enrollment of patients with KRAS G12C-mutant NSCLC who are either naïve to or previously treated with a KRAS G12C inhibitor is ongoing in the expansion phase of RAMP 203.
  • “Given KRAS G12C mutations are the most common KRAS mutation in NSCLC and acquired mutations and amplifications occur upon clinical progression to KRAS G12C inhibitor monotherapy, the results of the RAMP 203 trial are important in understanding potential new treatment approaches for patients.”

ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial

Retrieved on: 
Monday, September 11, 2023
Biotechnology, FDA, Health, Clinical Trials, Oncology, Neutropenia, Belfer Center for Science and International Affairs, Central nervous system, American Journal of Clinical Oncology, Progression-free survival, HER2, DCR, OS, Journal of Thoracic Oncology, International Association, Lung cancer, ILD, Pneumonitis, NSCLC, Lung, Doctor of Philosophy, AstraZeneca, PFS, Journal, Dor, MD, Patient, Daiichi Sankyo, Anemia, CR, ADC, CRS, Diagnosis, R, George M. Low Center for Industrial Innovation, Conference, ORR, Disease, Dana–Farber Cancer Institute, Medical imaging, Copper, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).

Key Points: 
  • Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC).
  • Median OS was 19.5 months (95% CI: 13.6-NE) in the 5.4 mg/kg arm and not reached (95% CI: 12.1-NE) in the 6.4 mg/kg arm.
  • Baseline central nervous system metastases were present in 34.3% of patients in the 5.4 mg/kg arm and 44.0% of patients in the 6.4 mg/kg arm.
  • Median follow-up was 11.5 months (range 1.1-20.6) in the 5.4 mg/kg arm and 11.8 months (range 0.6-21.0) in the 6.4 mg/kg arm.

Leaders in Breast and Lung Cancer treatment join SystImmune Inc's Clinical Science Advisory Committee

Retrieved on: 
Wednesday, April 26, 2023
IDeA Networks of Biomedical Research Excellence, TNBC, Memorial Sloan Kettering Cancer Center, Triple-negative breast cancer, Therapy, SPORE, CDK, Cancer and Leukemia Group B, Belfer Center for Science and International Affairs, Survival, Cancer, Lung cancer, Woman, MMSC, Research, NSCLC, CMO, CALGB, Immunotherapy, Biomarker, Associate, Oncology, Harvard Medical School, CSAC, Patient, UCSF, Breast cancer, Division, Susan, EGFR, MSK, Biology, ADC, Haematopoietic system, Antibody-drug conjugate, George M. Low Center for Industrial Innovation, Disease, Dana–Farber Cancer Institute, Medical device, Birth control, Medical imaging, Sacituzumab govitecan, Medicine

Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.

Key Points: 
  • Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.
  • They have led high-profile clinical programs, including the development of Trodelvy (sacituzumab govitecan-hziy), the most recent drug approved for the treatment of triple-negative breast cancer (TNBC).
  • Their expertise will guide SystImmune in the advancement of its ADC pipeline into breast cancer.
  • Dr. Rugo is the director of UCSF's breast cancer clinical trials program and the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late-stage breast cancer.

Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

Retrieved on: 
Thursday, December 15, 2022
Antibody-drug conjugate, MD, IND, Doctor of Philosophy, Internal medicine, Brigham and Women's Hospital, Learning, Belfer Center for Science and International Affairs, Conjugation, Patient, Science, Cancer, University, Dana–Farber Cancer Institute, NSCLC, Oncology, Lung cancer, ADC, ASCO, CSO, Disease, Degenerative disease, Reality, George M. Low Center for Industrial Innovation, AACR, ESMO, Multimedia, Clinical trial, GM, DFCI, Hospital, SAB, Dana, Harvard Medical School, EGFR, Medical device, Duality, Medicine

PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Pasi A. Jnne as member of SAB.

Key Points: 
  • PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr. Pasi A. Jnne as member of SAB.
  • Dr. Pasi Jnne is a world renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Jnne's research combines laboratory-based study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer.
  • Dr. Yang Qiu, CSO and US GM of Duality, added, "We are very excited Dr. Pasi Jnne joined Duality SAB.

New Study to Address Cancer Treatment Resistance for People Who Are KRAS Positive

Retrieved on: 
Wednesday, November 30, 2022
Doctor of Philosophy, Patient, SAN, Drug resistance, Prevalence, Gene, Cancer, Harvard Medical School, Multimedia, Risk, KRAS, Large-cell lung carcinoma, Partnership, SPARK, RAS, Dana–Farber Cancer Institute, Lung cancer, George M. Low Center for Industrial Innovation, Travel, Survivor, Medicine, Drug development, MD, Colorectal cancer, Research, Addario Lung Cancer Medical Institute, Alchemy, Hope, Liquid biopsy, Survival, Foundation Medicine, FDA, Pharmaceutical industry, Medical imaging, Medical device

"The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.

Key Points: 
  • "The development of treatment resistance is unfortunately common in patients with lung cancers and other tumor types with the KRAS G12C mutation," said Dr. Awad.
  • "Treatment resistance is a harsh reality for too many people with lung cancer," said Richard Erwin, executive director of clinical operations at ALCMI.
  • SPARK Study blood samples will be analyzed to help advance research and treatment for KRAS-positive lung cancer.
  • "The SPARK study will research why KRAS-mutant cancers develop drug resistance, which will then fuel research into preventing and overcoming resistance.

Frontier Medicines Announces Distinguished Oncologist Dr. Pasi Jänne Joins its Scientific Advisory Board

Retrieved on: 
Thursday, July 14, 2022
Disease, Cancer, Hospital, Precision medicine, SAB, EGFR, George M. Low Center for Industrial Innovation, Belfer Center for Science and International Affairs, Mutation, Coronavirus Scientific Advisory Board (Turkey), Brigham and Women's Hospital, LinkedIn, University, Large-cell lung carcinoma, KRAS, Patient, SAN, Dana–Farber Cancer Institute, CEO, GLOBE, Internal medicine, Machine learning, Proteome, Mesothelioma, Research, Twitter, Lung cancer, Squamous cell carcinoma, Oncology, Frontier, Pharmaceutical industry, Medical device

We look forward to benefiting from his scientific prowess and experience as an expert oncologist.

Key Points: 
  • We look forward to benefiting from his scientific prowess and experience as an expert oncologist.
  • Dr. Jnne added, Frontier has a unique pipeline of programs targeting several key drivers of cancer, including activated KRASG12C.
  • Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable.
  • Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer.

Ontario strengthens its AI Ecosystem leadership position by extending partnerships with founding industry sponsors

Retrieved on: 
Tuesday, June 21, 2022
Industry, Vector Institute, University, Environment, Government, CEO, Toronto, Leadership, Research, Adoption, Engineering, Growth, Government of Ontario, George M. Low Center for Industrial Innovation, Ecosystem, Health, Mark (given name), Artificial intelligence, Partnership, Transport, Government of Canada, Deep learning, Federation, VP, CIFAR, Organization, Machine learning, AI, Medical device, Pharmaceutical industry, Vector

"We are grateful to our founding sponsors for their continued commitment to Vector, and for their commitment to the growth of the AI ecosystem in Canada.

Key Points: 
  • "We are grateful to our founding sponsors for their continued commitment to Vector, and for their commitment to the growth of the AI ecosystem in Canada.
  • Their renewed commitment with Vector will help secure Canada's leadership role in the field of AI, increasing our global competitiveness and improving the lives of all Canadians.
  • "AI will touch every sector of society, from health to transportation and transform almost all industries, making them more competitive.
  • Thank you to our sponsors for their renewed commitment to Vector and the AI ecosystem:

AI Experts to Discuss How Artificial Intelligence is Powering Manufacturing at Automate 2022

Retrieved on: 
Wednesday, June 8, 2022
Internet, Mobile, Wireless, Other Technology, Technology, Software, Automation, Success, Motion, Artificial intelligence, George M. Low Center for Industrial Innovation, Boston Dynamics, A3, Next wave, AI, Competition, Social robot, General Motors, AMR radiotelephone network (Czechoslovakia), Solution, Intel, Robotics, Control, Robot research initiative, Association, General officer, Medical device, Management, Conference, Accenture, NVIDIA, Internet, Mobile, Wireless, Other Technology, Technology, Software

Today at the Automate 2022 Show and Conference in Detroit, leading experts in artificial intelligence (AI) will discuss how to put AI to use in manufacturing facilities in the keynote panel, AI & Manufacturing - How Artificial Intelligence is Powering the Next Wave of Manufacturing.

Key Points: 
  • Today at the Automate 2022 Show and Conference in Detroit, leading experts in artificial intelligence (AI) will discuss how to put AI to use in manufacturing facilities in the keynote panel, AI & Manufacturing - How Artificial Intelligence is Powering the Next Wave of Manufacturing.
  • Technologists from Accenture, NVIDIA, General Motors, Landing AI and Intel will offer insights and best practices on how businesses can take advantage of AI to enhance their automation processes and improve efficiencies and productivity overall.
  • The synergies among AI and automation technologies are powering the next wave of manufacturing, and we want everyone to feel empowered with this knowledge to move forward after Automate.
  • To apply for a press pass, visit https://www.automateshow.com/form.cfm?form_id=151
    The Association for Advancing Automation (A3) is the leading global advocate for the benefits of automating.

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, February 15, 2022
New Drug Application, Patient, Colorectal cancer, Food, Cancer, KRAS, Judgement, PRMT5, Company, Dana–Farber Cancer Institute, Science, Lung cancer, SEC, Immunotherapy, Review, Solution, Authorization, SAN, Special access program, Nasdaq, Accelerated approval (FDA), Large-cell lung carcinoma, Pancreatic cancer, Therapy, LinkedIn, U.S. Securities and Exchange Commission, Twitter, Docetaxel, FDA, George M. Low Center for Industrial Innovation, PDUFA, NDA, NSCLC, Research, Multimedia, EAP, Trial of the century, Life, RTOR, Pharmaceutical industry, Facebook, Mirati

Food and Drug Administration(FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.

Key Points: 
  • Food and Drug Administration(FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
  • The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022.
  • The FDA's review of the adagrasib NDA marks important progress toward potentially providing a new, targeted option for those living with KRASG12C-mutated non-small cell lung cancer."
  • The Company has an ongoing confirmatory Phase 3 trial, KRYSTAL-12, evaluating adagrasib versus docetaxel in patients with second-line KRASG12C-mutated NSCLC.

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

Retrieved on: 
Wednesday, October 20, 2021
Dana–Farber Cancer Institute, Â, George M. Low Center for Industrial Innovation, Twitter, Private Securities Litigation Reform Act, SRA, COVID-19, Hospital, Lung cancer, LinkedIn, Harvard Medical School, Precision medicine, Degenerative disease, Pharmacology, Goal, Systems biology, Mutation, Research, Stanford University School of Medicine, Chemistry, Nasdaq, Laboratory, Pathology, Associate, Therapy, GLOBE, Nathanael Gray, Patient, Translation, Industry, Science, Biochemistry, Solution, Research and development, Trial of the century, EGFR, Pharmaceutical industry

STAMFORD, Conn., Oct. 20, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into an exclusive worldwide license agreement with Dana-Farber Cancer Institute (Dana-Farber) and a sponsored research agreement (SRA) with Stanford Medicine for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) designed for the treatment of EGFR-mutant lung cancers. The portfolio, which was originally developed in the laboratory of Nathanael Gray, Ph.D., Professor of Chemical and Systems Biology, Co-Director of Cancer Drug Discovery, and Co-Leader of the Cancer Therapeutics Research Program at Stanford Medicine, includes several differentiated, first-in-class chemical series representing novel approaches to targeting mutant EGFR and is designed to address both de novo oncogenic drivers and emerging resistance mutations to existing EGFR inhibitors. The most advanced asset in the portfolio is currently in lead optimization and targets the C797S resistance mutation.

Key Points: 
  • The most advanced asset in the portfolio is currently in lead optimization and targets the C797S resistance mutation.
  • We are very pleased to expand our portfolio with the in-license of these selective and differentiated EGFR inhibitors, which are complementary to our strategy of developing novel targeted therapies for patients with biomarker-defined solid tumors, said Saqib Islam, Chief Executive Officer of SpringWorks.
  • In addition to the monotherapy opportunities in lung cancer, where a significant unmet medical need remains, these EGFR inhibitors provide several avenues for combination therapy development as well.
  • This SRA is intended to support lead optimization and translational biology efforts as the portfolio advances towards development candidate nomination.